Andrew Baxter - Concepedia

Author

Andrew Baxter

British American Tobacco (United Kingdom)ORCID

Also Known As

A J Baxter, A. Baxter, A. J. BAXTER, A. J. Baxter, A. J. G. BAXTER, A.J. Baxter, ANDREW J. G. BAXTER, Andrew Baxter, Andrew J Baxter, Andrew J. Baxter

108

Publications

2.4K

Citations

H-Index

133

Concepts

All Affiliations

British American Tobacco (United Kingdom)Loughborough University AstraZeneca (United Kingdom)Royal Hallamshire Hospital Chilworth Technology (United Kingdom)

About

Andrew Baxter is an author at British American Tobacco (United Kingdom) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	32	1.3K
2	Natural Sciences	11	14	373
3	Engineering	7	7	208
4	Health Sciences	1	1	18
5	Humanities	1	1	212

Andrew Baxter

Publications

Citations

H-Index

Page 1

	Year	Citations
Dehiscence of the Fallopian canal An anatomical study Andrew Baxter The Journal of Laryngology & Otology Fallopian CanalGross AnatomyHumanitiesGet Access LinkMorphology	1971	212
Swallowing food without chewing; a simple way to reduce postprandial glycaemia N W Read, I. Welch, Catherine Austen, British Journal Of Nutrition	1986	137
Undiagnosed Intratemporal Facial Nerve Neurilemomas Hirohisa Saito, Andrew Baxter Archives of Otolaryngology - Head and Neck Surgery Small NeurilemomasGross AnatomyNeuroanatomyMedicineAnatomy	1972	121
Hit-to-Lead studies: The discovery of potent adamantane amide P2X7 receptor antagonists Andrew Baxter, Janice Bent, Keith Bowers, Bioorganic & Medicinal Chemistry Letters Drug TargetBiochemistryFunctional SelectivityMedicineRational Drug Design	2003	117
Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors Andrew Baxter, Steve Brough, Anne Cooper, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryThiophenecarboxamide Ikk-2 InhibitorsHit IdentificationDrug TargetBiochemistry	2004	90
2-cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV Doreen M. Ashworth, Butrus Atrash, Graham R. Baker, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryMedicineNatural SciencesPeptoid	1996	80
Targeted omics analyses, and metabolic enzyme activity assays demonstrate maintenance of key mucociliary characteristics in long term cultures of reconstituted human airway epithelia Andrew Baxter, Simon C. Thain, Anisha Banerjee, Toxicology in Vitro Lung InflammationPathologyRespiratory EpitheliaKey BiomarkersMetabolic Enzyme Activity	2015	60
Reduced biological effect of e-cigarette aerosol compared to cigarette smoke evaluated in vitro using normalized nicotine dose and RNA-seq-based toxicogenomics Linsey E. Haswell, Andrew Baxter, Anisha Banerjee, Scientific Reports	2017	60
Novel P2X7 receptor antagonists Lilian Alcaraz, Andrew Baxter, Jos Bent, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicineMechanism Of ActionReceptor (Biochemistry)Pharmacological Agent	2003	58
Hit-to-Lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists Andrew Baxter, Anne Cooper, Elizabeth Kinchin, Bioorganic & Medicinal Chemistry Letters Drug TargetBiochemistryMedicineRational Drug DesignPharmacological Agent	2005	54

Page 1